parameters determined with gas inhalation labeled 150 steady-state PET studies. The asymmetry index (AI) i.e., the percentage of the activity rate of the ischemic MCA territory versus the contralateral one, was deter mined by SPECT. Acetazolamide reactivity expressed as AAI, or change in AI after acetazolamide challenge, was
Various hemodynamic parameters determined with positron emission tomography (PET) can as sess the circulatory and metabolic state in the brain. Increases in cerebral blood volume (CBV) and CBV/CBF ratio occur as a result of the autoregula-significantly lower in seven patients than -8.4%, the lower limit of the 95% confidence interval for the normal reactivity. Values of ipsilateral CBF, cerebral blood vol ume (CBV)/CBF, and oxygen extraction fraction (OEF) and contralateral OEF were significantly different be tween patients with normal and reduced acetazolamide reactivity. Values of AAI were correlated with OEF (r = -0.87; p < 0.00 1) and CBV/CBF (r = -0.56; p < 0.05). All patients with OEF >0.52, the mean + 2 SD calculated from five normal volunteers, also had reduced acetazol amide reactivity, while the patients with normal OEF val ues had normal reactivity. The present study has demon strated that SPECT studies with an acetazolamide chal lenge can detect the Stage II hemodynamic failure. Key Words: Acetazolamide-Hemodynamic reserve-1 2 3I
IMP-PET -SPECT.
tory vasodilatation and prolongation of mean transit time for maintaining CBF when cerebral perfusion pressure drops (Stage I). If cerebral perfusion pres sure decreases further and vasodilatation becomes maximal, CBF also begins to decrease, but a com pensatory increase in oxygen extraction fraction (OEF) maintains cerebral oxygen metabolism con stant (Stage 11 ). Measuring CBV, CBV/CBF, and OEF allows quantitative determination of the de gree of hemodynamic compromise in patients with occlusive cerebral arterial disease (Grubb et al. , 1973; Powers et aI. , 1987; Powers, 199 1) . However, PET cannot be applied routinely to stroke patients, because it is expensive and not commonly avail able. Acetazolamide is a potent cerebral vasodilator (Mithoefer et aI., 1957) and is increasingly being used to assess hemodynamic reserve in the brain in combination with 133Xe inhalation, cold Xe com puted tomography (CT), single photon emission computed tomography (SPECT), or transcranial Doppler ultrasonography (Vorstrup et al. , 1986; Sullivan et al., 1987; Sorteberg et al., 1989; Rogg et al. , 1989; Knop et aI. , 1992; Hasegawa et al. , 1992; Chimowitz et al. , 1993) . A SPECT study with acet azolamide challenge can three-dimensionally image brain areas with reduced vasodilatory capacity, which are potentially vulnerable to further reduc tion in cerebral perfusion pressure. Although pa tients with reduced acetazolamide reactivity on SPECT have been reported to have angiographic evidence of major cerebral artery occlusion with inadequate collateral and clinical features of hemo dynamic stroke (Knop et aI. , 1992; Hasegawa et al., 1992) , there has been no study evaluating the rela tionship of acetazolamide reactivity with hemody namic and metabolic parameters as determined by PET.
The true mechanism of cerebral vasodilatation by acetazolamide remains unresolved. It was reported that the vasodilatation is mediated by inhibition of carbonic anhydrase, which is localized in the brain and circulating red blood cells (Posner and Plum, 1960; Maren, 1967 Maren, , 1977 . Acetazolamide induces a local extracellular acidosis in the brain that triggers an increase in CBF as CO 2 does (Wang et al. , 1993) . Because acetazolamide reactivity does not directly represent the pressure autoregulation, but instead represents chemical vasodilatatory capacity, SPECT studies with an acetazolamide challenge may not be adequate to detect hemodynamic fail ure. Acetazolamide inhibits washout of CO 2 from brain tissues. This mechanism, however, raises the possibility that reduced acetazolamide reactivity may indicate low CO 2 production in tissues with low metabolic activities and may have no relation ship to true vascular reactivity.
The aim of the present study was to validate the accuracy of SPECT study with acetazolamide chal lenge for evaluating hemodynamic reserves in the brain and to determine the potential effect of local metabolic activities on the acetazolamide reactiv ity. We compared PET parameters with acetazol amide reactivity as determined with N-isopropyl-p e 2 3I]-iodoamphetamine (1 2 3I-IMP) SPECT in pa tients who had occlusive disease in major cerebral arteries but no or only a small infarction on CT and magnetic resonance imaging (MRI) . We used 1 2 3 1 _ IMP because the initial distribution of 1 2 3 1 _ IMP ac curately represents regional CBF (Kuhl et al. , 1982) and is particularly suitable for detecting a high-CBF
J Cereb Blood Flow Metab. Vol. 14, No.5, 1994 condition, as is expected to occur following acet azolamide challenge (Nishizawa et aI., 1989) .
SUBJECTS AND METHODS

Patients
Among the patients who were admitted to our hospital (Cerebrovascular Division, Department of Medicine, Na tional Cardiovascular Center, Osaka, Japan) between January 1, 1992, and April 31, 1993, we studied 14 pa tients who had a unilateral occlusion or severe stenosis (>75% in diameter) of the internal carotid artery (lCA) or the trunk of the middle cerebral artery (MCA) with min imal or no infarction on CT and MRI. They were eight men and six women, with a mean age of 65.4 years (range, 48-81 y). Conventional angiography or digital subtraction intraarterial angiography and brain CT and MRI were per formed in all patients before hemodynamic studies using PET and SPECT with an acetazolamide challenge. The potential mechanism of stroke in each patient was clini cally diagnosed and classified into the categories of ar tery-to-artery (A-to-A) embolic, hemodynamic, and un classified, which were modified from the National Insti tute of Neurological Disorders and Stroke (NINDS) Classification of Cerebrovascular Disease III (NINDS Ad Hoc Committee, 1990) . A-to-A embolism was diagnosed in patients without a cardiac source of emboli when (a) intraluminal filling defects suggesting emboli or recanali zation of the previously occluded arteries were confirmed angiographically or (b) a hemorrhagic infarction was de tected with CT or MRI. Patients with a potential cardiac source of emboli were excluded from the study. Hemo dynamic transient ischemic attack or stroke was diag nosed, when (a) hemodynamic episodes, such as ortho static hypotension, and excessive antihypertensive med ication were evident immediately before the stroke onset or (b) fluctuation of neurological symptoms and signs was accompanied by orthostatic posture, drop in blood pres sure, or both. Patients not fitting these criteria were grouped as "unclassified."
The cerebrovascular risk factors were hypertension in 11 patients, diabetes mellitus in four, and hyperlipidemia in nine. Atherosclerotic vascular lesions were present in the ICA in 10 patients and the trunk of the MCA in five. Infarction in the MCA territory was not evident on CT and MRI in nine patients. The other five patients had smalliacunes or small cortical infarcts in the MCA terri tory. The strokes of the 14 patients were hemodynamic in four patients, A-to-A embolic in two, and unclassified in eight. Clinical and neuroradiological features of each pa tient are summarized in Table 1 . All patients were exam ined by PET and SPECT for this study >4 weeks after stroke onset, when their neurological conditions became stable.
Five healthy volunteers with a mean age of 48.0 years (range, 30-64) underwent PET studies to determine nor mal values. There were three men and two women, and they were free of cerebrovascular risk factors and neuro logic symptoms and signs. No focal brain lesions were detected with CT and MRI in these subjects.
Methods
SPECT with acetazolamide challenge. Regional va sodilatory capacity was determined by means of 1 2 31_IMP
SPECT with an acetazolamide challenge. SPECT studies 
both with and without acetazolamide were carried out in each patient with (a) a conventional rotating 'Y camera (Starcam 400 AC/T; General Electric, Milwaukee, WI, U.S.A.) with a 12-mm full width at half-maximum (FWHM) obtained from 64 projections and displayed on a 64 x 64 matrix, at sampling times of 20--30 s, with a gen eral all-purpose collimator, or (b) a ring-type 'Y camera (Headtome SET-070; Shimadzu, Kyoto, Japan) with a 8-mm FWHM obtained from a 20-min acquisition onto a 128 x 128 matrix using a general all-purpose collimator. The acetazolamide challenge was done 3 days after the baseline SPECT measurement. Acetazolamide (1,000 mg) was given i.v. 15 min before 4.5 mCi (166.5 MBq) of 1 2 3I_IMP (Nihon Mediphysics, Takarazuka, Japan). Data collection began 15-30 min after the tracer was injected, with patients supine with eyes covered. Data were ob tained from 64 projections and displayed on a 64 x 64 matrix, with each sampling time being 20--30 s. All data were corrected for an attenuation of O.l/cm. The tomo graphic data were reconstructed using a filtered back projection algorithm. Slice thickness was 6 mm.
PET. A PET study was carried out within 2 weeks be fore or after the SPECT study, since it is technically un feasible to perform these studies simultaneously. Re gional CBF, OEF, cerebral metabolic rate for oxygen (CMR0 2 ), and CBV were measured with a Headtome IV PET scanner (Shimadzu, Kyoto, Japan) with a spatial resolution of 4.5 mm at FWHM and the 150-labeled gas inhalation technique (Frackowiak et aI., 1980; Lam mertsma et aI., 1981 ). An emission scan with an external 68Ge-68Ga ring source was corrected for the effects of tissue attenuation by corresponding transmission scans. A transmission scan was carried out with the patient su pine with eyes closed. Separate scans were performed during continuous inhalation of 150-labeled carbon diox ide (CI50 2 ) and molecular oxygen e50 2 ) for the measure ment of CBF and OEF, respectively. The third scan, for the measurement of CBV, was carried out after 2 min of inhalation of 150-labeled carbon monoxide (CI50) (Mar tin et aI., 1987; Lammertsma et aI., 1987) . During the scans, serial blood samples were obtained through a fine gauge radial (or brachial) artery catheter for measuring arterial isotope activity, arterial oxygen content (0 2 C), and arterial Pe0 2 . CMR0 2 was calculated as CBF x OEF x 0 2 C, Data analysis. A SPECT image plane where asymme try of radioisotope (RI) distribution between the ipsilat eral and contralateral MCA territory was most prominent was selected for data analysis for each measurement. In each patient, the size and location of a region of interest (ROI) were made equivalent between the SPECT and PET studies. A rectangular ROI 3 cm (transverse) x 5 cm (longitUdinal) was located in the center of the MCA ter ritory. If an infarct was included within this standard ROI, the size of the ROI was reduced to 8 cm 2 to avoid the infarct. In SPECT studies, an asymmetry index (AI)-the per centage of RI activity of a ROI in the ipsilateral MCA territory compared with that in the contralateral homolo gous ROI-was used for numerical evaluation of relative 1 2 3I_IMP distribution. According to our previous study (Hasegawa et aI., 1992) , the vasodilatory capacity was expressed as ilAI, as calculated by the following equa tion: ilAI = (AI during acetazolamide challenge) -[1.03 x (baseline AI) -3.98]. This equation was obtained from the regression line of AI during acetazolamide challenge J Cereb Blood Flow Metab. Vol. 14, No.5, 1994 (y) with baseline AI (x)-y = 1.03x -3.98 (r = 0.993; p < O.01)-for 10 control patients (average age, 62.7 years) without significant cerebral arterial lesions. Because we confirmed that ilAI values make a normal distribution and their 95% confidence interval was + 8.4 to -8.4%, we diagnosed patients with ilAI < -8.4% as having re duced vasodilatory capacity (or a positive acetazolamide test).
Local PET parameters in the ROI were used for calcu lating mean CBF, CBV, CMR0 2 , OEF, and CBV/CBF values in each hemisphere. The values were used for comparison with ilAI on the SPECT study. Values of PET parameters were judged as abnormal when they were out of the range of mean ± 2 SD of the normal controls.
Patients were classified into two groups according to acetazolamide reactivity on SPECT, the positive group having a ilAI < -8.4% and the negative group -8.4% or higher. We compared each PET parameter between the two groups by unpaired t test and determined relation ships of ilAI with PET parameters by linear-regression analysis and Pearson correlation coefficient. The two tailed probability <0.05 was considered significant. Table 1 ). They were not sig nificantly different in age or frequencies of various cerebrovascular risk factors than patients with a negative acetazolamide test. Arterial pH, Po 2 , Peo 2 , and blood pressure were stable in every pa tient during PET studies and were not different be tween patients with positive and negative acetazol amide tests.
RESULTS
Seven patients had reduced vasodilatory capaci ties on the SPECT study with acetazolamide chal lenge (patients 8-14 in
The patients with positive acetazolamide tests had significantly lower CBFs, higher CBV/CBF ra tios, and higher OEFs in the ipsilateral MCA terri tory than did the negative group (Table 2) . CMR0 2 was comparable between the two groups. Similar trends were observed and the difference in OEF was again significant in the contralateral hemi sphere. The positive group had significantly higher OEF values in the contralateral hemisphere than did the negative group.
Ipsilateral OEF values had a significantly nega tive correlation with LlAI (r = -0.87; P < 0.001; Fig. 1 ). Significantly negative correlations were ob served between ipsilateral CBV /CBF and LlAI (r = -0.56; P < 0.05; Fig. 1 ). Ipsilateral CBF, CBV, and CMR0 2 had no significant relation with LlAI (Fig. 1) .
In healthy controls, values of PET parc:tmeters obtained from hemispheric ROI, which were iden tical in size and location to those of the studied patients, were 36.3 ± 5.7 (mean ± SD) ml 100 g-l min-1 in CBF, 2.47 ± 0.48 ml 100 g-l in CBV, 0.069 ± 0.0 12 min in CBV/CBF, 0.42 ± 0.05 in OEF, and 2. 59 ± 0.37 ml 100 g-l min -1 in CMR0 2 . There were no significant changes in these values with advancing age. All patients with ipsilateral OEF values >0.52, the mean + 2 SD of normal OEF values, had reduced acetazolamide reactivity, but none of the patients with lower ipsilateral OEF values did so. Reduced acetazolamide reactivity, however, did not accurately represent abnormality of CBV/CBF; 3 of 10 patients with high CBV/CBF ratios (>0.093 min) had normal reactivity (Table 3) .
DISCUSSION
In the present study, we observed significantly negative correlations of LlAI with the OEF and the CBV /CBF ratio within the noninfarcted areas in the A 8
ipsilateral MCA territory in patients with a unilat eral occlusion or severe stenosis of the ICA or trunk of the MCA. Patients with reduced acetazolamide reactivities had significantly lower CBFs and higher CBV /CBF ratios but similar CMR0 2 values to those of patients with normal acetazolamide reactivity. Reduced acetazolamide reactivity corresponded perfectly to elevated OEF, but an increase in the CBV/CBF ratio was sometimes overlooked on SPECT studies. These results indicate that reduc tion in acetazolamide reactivity represents the Stage II hemodynamic failure determined with PET studies (Powers et aI., 1987; Powers, 199 1) . We could eliminate the possibility of a cause-effect re lationship between the metabolic activity of the brain and the acetazolamide reactivity, because aAI had no relationship to CMR02• Although brain vessels in necrotic tissues with very low CMR02 values are unlikely to respond to acetazolamide, we carefully excluded such areas from the present ROI analyses.
We examined five healthy controls to determine the normal values of PET parameters. The control data obtained from the present series were fairly comparable with those determined with similar PET equipment (Yamaguchi et aI. , 199 1) . Our controls in the PET studies were younger in age than the pa tients (48.0 ± 12. 0 and 65.4 ± 9.3, respectively), raising the possibility that the control values are not appropriate for comparison with patient data, al though we did not detect any age-related change in PET parameters. Previous studies have reported that gray matter CBF, CBV, and/or CMR02 de crease with advancing age, but gray matter OEF and CBV/CBF (or CBF/CBV) and all PET param eters in white matter remain fairly stable (Frackow iak et aI. , 1980; Pantano et aI. , 1984; Yamaguchi et aI. , 1986; Leenders et aI. , 1990) . Therefore, at least for OEF and CBV/CBF, the values in controls can be used as the standard when evaluating the hemo dynamic state in each patient.
Before this study began, we had speculated that acetazolamide reactivity, as expressed by aAI, might correlate better with CBV/CBF as the mean transit time (or CBFICBV as an indicator of auto regulatory vasodilatation) than with OEF, because the mean transit time becomes prolonged due to autoregulatory vasodilatation in brain tissues with lowered cerebral perfusion pressure (Gibbs et aI. , 1984) . Although both OEF and CBV/CBF (and CBFICBV; data not presented) correlated signifi- cantly with aAI, the correlation was better and more linear in the former than in the latter. The patients who had elevated CBV ICBF values and normal OEFs (patients 1, 3, and 7 in Table 3 ), being in Stage I hemodynamic failure (Powers et aI., 1987; Powers, 1991) , did not also have reduced acetazol amide reactivity. Therefore, our SPECT studies with acetazolamide challenge were not sensitive enough to reveal Stage I failure.
Prior PET studies correlating CO2 reactivity with PET parameters demonstrated that vascular re sponsiveness to change in P aco2 was negatively cor related with OEF and that metabolic reserve as ex pressed by OEF was utilized before exhaustion of the perfusion reserve (Kanno et aI. , 1988; Herold et aI., 1988) . These studies and the present one indi cate that chemical vasodilatory capacity as deter mined by CO2 or acetazolamide responsiveness may have a closer relationship with metabolic re serve than with pressure autoregulation. The failure of the present SPECT study to detect Stage I he modynamic compromise might have been caused by the large ROI setting, lack of measurement of absolute CBF values, poor spatial resolution, and/ or the potential of overestimation of ipsilateral vas cular reactivity by using the data from contralateral ROI as the reference when hemodynamic reserve may be compromised.
We used the asymmetry index by dividing ipsilat eral RI activity by contralateral RI activity to over come the lack of absolute CBF values in the SPECT studies. The aAI value, however, might have over estimated the true acetazolamide reactivity if it was also depressed in the contralateral ROI. Patients with positive acetazolamide tests had relatively high OEF values even in the contralateral hemi sphere (Table 2) compared with normal values, making the difference of contralateral OEF values significant between the groups. Although the differ ence was not significant, the CBV/CBF ratio had a similar trend. These results indicate that there might be hemodynamically compromised tissues in the contralateral ROI in patients with reduced ac etazolamide reactivity, although we carefully ex cluded patients with contralateral arterial lesions and brain infarctions. In a PET study of unilateral ICA occlusion (Yamauchi et ai., 1990) , an increase in OEF was observed in border zone areas of the contralateral hemisphere. Mild but diffuse arterio sclerosis may increase CBV/CBF and OEF contra laterally, even when angiographically significant ar terial lesions are not evident. It has been reported that hypertensive subjects without significant arte rial lesions frequently have decreased CBFs and in creased OEFs (Fujii et ai., 1990) .
Lack of absolute CBF values in the SPECT study raises another problem: the inability to detect a par adoxical decrease in CBF within the hemodynami cally compromised tissues following injection of the vasoactive drug. This phenomenon, the "intracere bral steal," was reported in prior studies using ac etazolamide (Vorstrup et ai., 1984 (Vorstrup et ai., , 1986 , and it may induce neurologic deterioration. In our previ ous work, acetazolamide administration was not ac companied by any change in neurological state, electroencephalogram, and somatosensory evoked potentials in 23 patients with ischemic stroke who were evaluated > 1 month after stroke onset (Ha segawa et ai., 1989).
In conclusion, the present study demonstrated that SPECT studies with an acetazolamide chal lenge can detect Stage II hemodynamically compro mised tissues. Although there are several limita tions, the study is useful for evaluating and moni toring the hemodynamically compromised state and adds to understanding of the pathophysiology of pa tients with chronic ischemic stroke.
